Portal:COVID-19/CoveredPWs

From WikiPathways

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
| SARS-CoV-2 and COVID-19 Pathway|| Collaborative project for curation of biological processes <br/> involved in the COVID-19 disease after SARS-Cov-2 infection.  || [https://www.wikipathways.org/index.php/Pathway:WP4846 WP4846] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved
| SARS-CoV-2 and COVID-19 Pathway|| Collaborative project for curation of biological processes <br/> involved in the COVID-19 disease after SARS-Cov-2 infection.  || [https://www.wikipathways.org/index.php/Pathway:WP4846 WP4846] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved
|-
|-
-
| Hijack of Ubiquitination by SARS-CoV-2 ||  || [https://www.wikipathways.org/index.php/Pathway:WP4860 WP4860] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved
+
| Hijack of Ubiquitination by SARS-CoV-2 || SARS-CoV-2 includes a novel Orf10 that interacts with <br/> multiple members of the Cullin 2 ubiquitin ligase complex. || [https://www.wikipathways.org/index.php/Pathway:WP4860 WP4860] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved
|-
|-
-
| Type I Interferon Induction and Signaling During SARS-CoV-2 Infection || || [https://www.wikipathways.org/index.php/Pathway:WP4868 WP4868] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
+
| Type I Interferon Induction and Signaling During SARS-CoV-2 Infection || The induction and signaling of type I interferon  <br/>  with specific SARS-CoV-2 protein and relevant drug. || [https://www.wikipathways.org/index.php/Pathway:WP4868 WP4868] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
|-
|-
-
| COVID-19, thrombosis and anticoagulation || || [https://www.wikipathways.org/index.php/Pathway:WP4927 WP4927] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
+
| COVID-19, thrombosis and anticoagulation || A commonly seen phenotype in patients suffering from Corona || [https://www.wikipathways.org/index.php/Pathway:WP4927 WP4927] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
|-
|-
-
| Activation of NLRP3 Inflammasome by SARS-CoV-2 || || [https://www.wikipathways.org/index.php/Pathway:WP4876 WP4876] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
+
| Activation of NLRP3 Inflammasome by SARS-CoV-2 || Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. || [https://www.wikipathways.org/index.php/Pathway:WP4876 WP4876] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
|-
|-
| SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor: <br/> Molecular mechanisms and potential therapeutic target || || [https://www.wikipathways.org/index.php/Pathway:WP4883 WP4883] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor: <br/> Molecular mechanisms and potential therapeutic target || || [https://www.wikipathways.org/index.php/Pathway:WP4883 WP4883] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress

Revision as of 19:35, 9 September 2020

Title Comment Links WP Category Status
SARS-CoV-2 and COVID-19 Pathway Collaborative project for curation of biological processes
involved in the COVID-19 disease after SARS-Cov-2 infection.
WP4846 SARS-CoV-2 Pathways Approved
Hijack of Ubiquitination by SARS-CoV-2 SARS-CoV-2 includes a novel Orf10 that interacts with
multiple members of the Cullin 2 ubiquitin ligase complex.
WP4860 SARS-CoV-2 Pathways Approved
Type I Interferon Induction and Signaling During SARS-CoV-2 Infection The induction and signaling of type I interferon
with specific SARS-CoV-2 protein and relevant drug.
WP4868 SARS-CoV-2 Pathways In Progress
COVID-19, thrombosis and anticoagulation A commonly seen phenotype in patients suffering from Corona WP4927 SARS-CoV-2 Pathways In Progress
Activation of NLRP3 Inflammasome by SARS-CoV-2 Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. WP4876 SARS-CoV-2 Pathways In Progress
SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor:
Molecular mechanisms and potential therapeutic target
WP4883 SARS-CoV-2 Pathways In Progress
COVID-19 AOP WP4891 SARS-CoV-2 Pathways In Progress
nsp9/nsp10-mediated SARS-CoV-2 pathogenesis WP4884 SARS-CoV-2 Pathways In Progress
LDLRAD4 pathway in COVID-19 WP4904 SARS-CoV-2 Pathways In Progress
Overview of perturbations to host-cell autophagy,
induced by distinct proteins of SARS-CoV-2
WP4936 SARS-CoV-2 Pathways In Progress
Coronavirus lipid metabolism WP4853 Other coronaviruses In Progress
Host-pathogen interaction of human corona viruses - autophagy WP4863 Other coronaviruses In Progress
Host-pathogen interaction of human corona viruses - apoptosis WP4864 Other coronaviruses In Progress
SARS coronavirus and innate immunity WP4912 Other coronaviruses In Progress
ER stress response in Coronavirus infection WP4861 Other coronaviruses In Progress
Downregulation of ACE2 expression by SARS-CoV
infection and SARS-CoV Spike protein
WP4799 Other coronaviruses In Progress
Host-pathogen interaction of human
corona viruses - MAPK signaling
WP4877 Other coronaviruses In Progress
Host-pathogen interaction of human
corona viruses - Interferon induction
WP4880 Other coronaviruses In Progress
ACE Inhibitor Pathway WP554 ACE2 In Progress
Metabolism of Angiotensinogen to Angiotensins (Reactome) WP2729 ACE2 In Progress

Pathway categories

The pathways on this portal are grouped in the following categories: SARS-CoV-2 Pathways, Other coronaviruses (e.g. MERS, SARS-CoV) and virus-host specific interactions (e.g. ACE2).

Contact us

Send questions about WikiPathways to the wikipathways-discuss mailing list.

How to add a pathway to the portal

The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact the administrator.

Personal tools